Mantle Cell Lymphoma (MCL) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Mantle Cell Lymphoma Emerging Therapy and TPP Insights

Thelansis’s “Mantle Cell Lymphoma (MCL) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Mantle Cell Lymphoma Overview

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma commonly linked to t(11;14) and cyclin D1 overexpression, driving cell-cycle progression. Its course ranges from indolent disease to aggressive forms; features include lymphadenopathy, splenomegaly, blood/bone-marrow involvement and gastrointestinal involvement. TP53 alterations, blastoid morphology and a high Ki-67 index signal higher-risk disease. Treatment is guided by disease biology, burden, age and fitness; carefully selected asymptomatic patients may be observed, while others receive immunochemotherapy with or without a covalent BTK inhibitor. Relapsed disease options include pirtobrutinib and CD19-directed CAR T-cell therapy. Sonrotoclax, a BCL-2 inhibitor, received accelerated FDA approval in May 2026 for relapsed or refractory MCL after at least two systemic lines, including a BTK inhibitor. BTK degraders and CD20×CD3 bispecifics remain investigational. Relapse and treatment resistance remain challenges.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)